By Teddy Lyons on May 11, 2023
Cancer sucks. Everyone knows someone who has been affected by this deadly disease. And while treatment has come a long way, there is still no cure. The disease kills more than 600,000 people in the United States every year. Billions of dollars have been poured into cancer drug development for decades… but to no avail. Oncolyze, the anti-cancer biotech startup I’m introducing to you today, has some of the most promising efficacy data that…
By Early Investing on January 11, 2021
Seed stage investing in pharma and biotech companies is a little different than seed stage investing in other sectors. When pharma and biotech companies approach crowdfunders, they’re usually pre-clinical — which means that human trials haven’t begun yet. And they’re raising amounts of money that can’t possibly sustain…
By Early Investing on September 8, 2019
In this week’s Mailbag, the Early Investing team explores investing in new sectors and understanding why the Fed is lowering interest rates.